On October 20, 2021 Doma announced the official start of its operation and plans to build its new drug development headquarters in Suzhou Industrial Park (Press release, Doma Biopharmaceutical, OCT 20, 2021, View Source [SID1234636132]). Doma was established in Suzhou BioBAY in September 2021. Led by Biocytogen and supported by three major central enterprises, China Life, PICC and State Development and Investment Corp., as well as CMB International and Suzhou Industrial Park, the project involves the joint construction of an innovative drug incubation center and the investment of the first phase is expected to exceed RMB 1 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

By leveraging the innovative pipelines branched from the project integrum platform, Doma is committed to incubating new antibody drug companies in the park and establishing a new cradle of innovation for new drug development in China. the goal of the project integrum is to discover numerous potential first-in-class targets and novel antibody molecules over a period of 3-5 years. Incubatees in their early stages can leverage the large number of promising new targets and antibodies identified by the platform to reduce early-stage R&D spending and move their pipelines quickly into clinical stages, thereby greatly accelerating the R&D process